USPTO serial 90269990
BASILEA PHARMACEUTICA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- RIEPEL, CHRISTINA MAXINE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BASILEA PHARMACEUTICA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Basilea Pharmaceutica International Ltd.
Basel, CH
Other trademarks owned by Basilea Pharmaceutica International Ltd.
BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL
ALLSCHWIL, CH
Other trademarks owned by BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL
Basilea Pharmaceutica International Ltd.
Basel, CH
Other trademarks owned by Basilea Pharmaceutica International Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Evan A. Raynes
Evan A. Raynes SYMBUS LAW GROUP PLLC1775 I STREET, NW, SUITE 1150WASHINGTON, DC 20006United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use | ACTIVE | — |
| 005 | Pharmaceutical and veterinary products and preparations for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of allergy; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical purposes; clinical medical reagents | ACTIVE | — |
| 042 | Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Basilea Pharmaceutica International Ltd.
- Other trademarks owned by BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL
- Other trademarks owned by Basilea Pharmaceutica International Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named BASILEA PHARMACEUTICA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 5, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 5, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 11, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 10, 2024 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jan 10, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 19, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Dec 19, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 28, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 22, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 20, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 20, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 20, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 7, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 5, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 5, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 5, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 22, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 20, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 20, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 20, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 27, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 4, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 2, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 2, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 2, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 29, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 4, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 4, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 14, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 29, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 29, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 29, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 29, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 29, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 22, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 10, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 24, 2020 | NWAP | NEW APPLICATION ENTERED | — |